SCHEMBL2977127

SCHEMBL2977127

FC(F)(F)c1ccccc1-c1csc(C2CCN(C3CCCC3)CC2)n1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.45
SPHK2 Q9NRA0 1/20 0.42
SPHK1 Q9NYA1 1/20 0.42
VCP P55072 1/20 0.41
KDM2B Q8NHM5 1/20 0.41
SLC18A3 Q16572 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
FAAH O00519 3/20 0.38
MPL P40238 1/20 0.38
SCD5 Q86SK9 1/20 0.37
TRPA1 O75762 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CNR2 P34972 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
RBP4 P02753 1/20 0.34
ACP1 P24666 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4262112 0.80 HPGDS (0.53) L3MBTL1SPHK2SPHK1VCPMPL
SCHEMBL2980025 0.80 UCHL1 (0.46) SPHK2SPHK1VCPKDM2BSLC18A3
SCHEMBL2981893 0.79 SLC18A3 (0.50) L3MBTL1SLC18A3ALDH1A1FAAHSMN1; SMN2
SCHEMBL2982276 0.79 L3MBTL1 (0.43) L3MBTL1SPHK2SPHK1VCPALDH1A1
SCHEMBL2976495 0.79 FAAH (0.43) L3MBTL1KDM2BALDH1A1KDM4EFAAH
Bromide SCHEMBL2986402 0.79 HPGDS (0.52) L3MBTL1SPHK2SPHK1VCPMPL
SCHEMBL2976294 0.78 CASP3 (0.51) L3MBTL1SPHK2SPHK1KDM2BALDH1A1
SCHEMBL2970657 0.77 SMN1; SMN2 (0.39) L3MBTL1KDM2BSLC18A3ALDH1A1FAAH
SCHEMBL2973505 0.74 HSD11B1 (0.49) L3MBTL1SLC18A3ALDH1A1KDM4EFAAH
SCHEMBL2973488 0.74 NPC1 (0.42) L3MBTL1SPHK2SPHK1ALDH1A1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786143-B2 Thiazolyl piperidine derivatives HOFFMAN-LA ROCHE INC. (US) 2010-08-31 US claimed
EP-1945635-B1 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2009-05-06 EP claimed
CN-101243078-A Thiazolyl piperidine derivatives useful as h3 receptor modulators HOFFMANN LA ROCHE (CH) 2008-08-13 CN claimed
EP-1945635-A2 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2008-07-23 EP claimed
US-20070043083-A1 Thiazolyl piperidine derivatives HOFFMANN-LA ROCHE INC. 2007-02-22 US claimed
WO-2007020213-A2 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO claimed
US-7786143-B2 Thiazolyl piperidine derivatives HOFFMAN-LA ROCHE INC. (US) 2010-08-31 US disclosed
EP-1945635-B1 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2009-05-06 EP disclosed
CN-101243078-A Thiazolyl piperidine derivatives useful as h3 receptor modulators HOFFMANN LA ROCHE (CH) 2008-08-13 CN disclosed
EP-1945635-A2 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2008-07-23 EP disclosed
US-20070043083-A1 Thiazolyl piperidine derivatives HOFFMANN-LA ROCHE INC. 2007-02-22 US disclosed
WO-2007020213-A2 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043083-A1 Thiazolyl piperidine derivatives HRH3, HRH4, H1-3 L3MBTL1 3337/4885SPHK2 910/4885SPHK1 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.